Find Oncology Drugs in Phase II Clinical Development in FRANCE

Lead Product(s): Tumor infiltrating lymphocytes

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Iovance Biotherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 13, 2020

Details:

Iovance Biotherapeutics will use TALEN® Technology from Cellectis to develop Gene-Edited TIL that have been genetically edited to create more potent cancer therapeutics.

Lead Product(s): Lacutamab,Gemcitabine,Oxaliplatin

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Innate Pharma will take the operational measures to reactivate the lacutamab TELLOMAK trial in Sézary syndrome and MF in France and UK, where regulatory agencies have authorized it.

Lead Product(s): Lacutamab,Gemcitabine,Oxaliplatin

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

Innate Pharma decided to suspend enrollment of new patients in the TELLOMAK trial, except in Italy where the clinical trial has been suspended.